News | December 07, 2021
RDIF offers vaccine for adolescents aged 12-17 in India
Sputnik M is a new member of the Sputnik vaccines family
Sputnik M is a new member of the Sputnik vaccines family
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
Subscribe To Our Newsletter & Stay Updated
